Must Reads by Date
Must reads for theWeek ending January 10, 2016
White and Gray Matter Damage in PPMS, Assessing the role of lesions
Cognitive Focus in Relapsing-Remitting MS, Associating perceptions with acceptance
Seizures in Multiple Sclerosis, Studying associations with lesions and GABA
CD59 Levels in Neuromyelitis Optica and Multiple Sclerosis, Compared with noninflammatory neurological disorders
Assessing Health State Values in 8 Dimensions, Does it add value?
Must reads for theWeek ending January 3, 2016
Quantitative MRI in Cortical Pathology, Studying gray matter lesions vs normal gray matter
Fatigue and Motor Control in MS, Assessing the effects of stimulation
Children of a Parent With MS, Evaluating their vulnerabilities
Discriminating Spinal Cord Sarcoidosis From Neuromyelitis Optica, What are the relevant features?
Gene Mutations in Focal Epilepsy, Identifying causative genes
Must reads for theWeek ending December 27, 2015
The Pathogenesis of Lacunar Stroke, Assessing associations in subtypes
Predicting Progression from MCI to AD, Markers in plasma and CSF hold predictive value
Surgical Exposure and Dementia, Is it a risk factor?
Radiosurgery in Cerebral Arteriovenous Malformations, Assessing durable benefits
Depression in MS Patients, Evaluating prevalence of therapy
Must reads for theWeek ending December 20, 2015
Axonal Loss in Optic Neuritis, Studying damage to the RNFL and GCC
Comorbidities in Myasthenia Gravis, Identifying the most common associations
Rituximab Therapy in MS and NMO, Assessing safety and efficacy over 50 patient years
AQP4 Antibodies in Lupus, Assessing their effect on neuromyelitis optica spectrum disorders
Fingolimod in Multiple Sclerosis, Evaluating changes in lymphocyte subset distribution
Must reads for theWeek ending December 13, 2015
Fingolimod as Second-line Therapy in RRMS, Comparing it with a second iDMT
MOG and AQP4 Antibodies in Neuromyelitis Optica, Studying their associations in children
Fingolimod in Relapsing Multiple Sclerosis, Comparing it with placebo
Genetic Factors in Multiple Sclerosis, How do they affect IFNβ response?
Disease-Modifying Drugs in RRMS, Associations with disability progression